XFOR

X4 Pharmaceuticals Inc

XFOR.US x4pharma.com
3.62
+0.12 (+3.29%)
USD · NASDAQ
52-week range
2.80
4.83
Trading at 40% of the 52-week range
Market Cap
347.01M
P/E Ratio
2.45
Forward P/E
0.00
Book Value
1.62
Div. Yield
N/A
% Institutions
100.14%
% Insiders
0.440%

1 Year

+6.1%

3 Year

-90.1%

10 Year

-99.9%
Description

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Company Information

Company Name
X4 Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US98420X2027
CIK: 0001501697
CUSIP: 98420X103
Currency: USD
Full Time Employees: 45
Phone: 857 529 8300
Fiscal Year End: December
IPO Date: Nov 16, 2017
Description:

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Address:

61 North Beacon Street, Boston, MA, United States, 02134

People

Directors & Officers

Name Title Year Born
Dr. Adam R. Craig M.B.A., M.D., Ph.D. Executive Chair 1966
Mr. John P. Volpone M.B.A. President & COO 1975
Mr. David H. Kirske CFO, Treasurer & Corporate Secretary 1954
Dr. Richard Peters M.D., Ph.D. Founder 1962
Dr. Renato T. Skerlj Ph.D. Founder NA
Dr. Keith T. Flaherty M.D. Founder & Member of Corporate Advisory Board 1971

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Oct 23, 2025 Adam R Craig N/A Purchase 86.21K $2.90 $250.00K
May 16, 2025 Mark Baldry N/A Purchase 1.03K $2.48 $2.56K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Morgan Stanley - Brokerage Accounts 9.47M Mar 31, 2026 9.55% $0.00 15.34%
FMR Inc 8.10M Mar 31, 2026 8.17% $0.00 -4.66%
Bain Capital Life Sciences Investors, LLC 7.97M Mar 31, 2026 8.04% $2.97 0.00%
Perceptive Advisors LLC 7.93M Jun 30, 2026 8.00% $0.56 17.75%
Kalehua Capital Management LLC 7.45M Mar 31, 2026 7.51% $11.83 100.00%
Saturn V Capital Management LLC 6.97M Jun 30, 2026 7.03% $4.67 8.00%
Empery Asset Management, LP 6.93M Jun 30, 2026 6.99% $37.43 -22.51%
Deep Track Capital, LP 5.88M Jun 30, 2026 5.93% $0.40 -7.27%
Vanguard Capital Management, LLC 3.50M Mar 31, 2026 3.53% $0.00 0.00%
BRAIDWELL LP 3.27M Mar 31, 2026 3.30% $0.45 -2.85%
Rosalind Advisors, Inc. 3.21M Mar 31, 2026 3.24% $5.33 23.36%
Blackstone Inc 2.68M Mar 31, 2026 2.71% $0.04 0.00%
Trails Edge Capital Partners, LP 2.57M Jun 30, 2026 2.59% $1.91 0.00%
Nantahala Capital Management, LLC 2.45M Mar 31, 2026 2.47% $0.37 0.00%
Bvf Inc 2.23M Mar 31, 2026 2.25% $0.29 0.00%
StemPoint Capital LP 1.70M Mar 31, 2026 1.72% $0.68 89.38%
Samsara BioCapital, LLC 1.40M Jun 30, 2026 1.41% $0.54 -23.85%
BlackRock Inc 1.21M Mar 31, 2026 1.22% $0.00 -1.22%
Woodline Partners LP 1.00M Mar 31, 2026 1.01% $0.02 0.02%
Geode Capital Management, LLC 939.73K Mar 31, 2026 0.95% $0.00 -0.08%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Small Cap Growth 3.39M 3.42% ▲ 0.00% Jun 30, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 2.60M 2.62% ▲ 0.00% Jul 31, 2026
3 Morgan Stanley Inception 2.31M 2.33% ▼ 1.07% Jun 30, 2026
4 Morgan Stanley Inst Inception I 2.31M 2.33% ▼ 1.07% Jun 30, 2026
5 iShares Russell 2000 ETF 1.96M 1.98% ▼ 0.57% Aug 31, 2026
6 EQ/Morgan Stanley Small Cap Growth K 1.92M 1.93% ▲ 5.40% Jul 31, 2026
7 Fidelity Small Cap Growth K6 1.69M 1.70% ▲ 0.00% Jun 30, 2026
8 Fidelity Select Biotechnology 1.43M 1.44% ▲ 0.00% Jul 31, 2026
9 Fidelity Advisor Biotechnology I 1.34M 1.35% ▲ 0.00% Jul 31, 2026
10 Vanguard Institutional Extnd Mkt Idx Tr 1.01M 1.02% ▼ 1.85% Jul 31, 2026

Financial Highlights

Market Cap: $347.01M
EBITDA: $-79.00M
P/E Ratio: $2.45
Book Value: $1.62
Earnings/Share: $1.43
Profit Margin: 0.00%
Operating Margin: -186.13%
ROA (TTM): -28.15%
ROE (TTM): -113.08%
Revenue (TTM): $15.85M
Revenue/Share (TTM): $0.16
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 346.30%

Valuation Metrics

Enterprise Value: $216.27M
Trailing P/E: 2.45
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 99.15M
Shares Float: 62.80M
% Insiders: 0.440%
% Institutions: 100.14%
Short % Float: 7.27%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$35.11M
Cost of Goods Sold
adjust
$-6.26M
Gross Profit
subtotal
$28.86M
SG&A
adjust
$-43.52M
R&D
adjust
$-72.22M
Operating Income
subtotal
$-86.88M
Other / Non-Operating Items
adjust
$7.68M
Net Income
subtotal
$-79.20M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about XFOR.US!